Using the Full Potential of Circulating Tumor Cells for Oncology Clinical Trials
August 19, 2021
Circulating tumor cell counts are powerful prognostic factors for cancer patients. Recent research has found that they can be quite heterogeneous – similar to the cells of the tumor they shed from. Novel tools that analyze the different phenotypes can reveal their full potential as biomarkers in oncology clinical trials.
Read the source article at Labiotech.eu
2021-07-26 10:35:29
